Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

NCT06676072 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).

Interventions

  • DEVICE PFA Ablation catheter

Study Locations (20)

Florida

  • HCA Florida Mercy Hospital — Miami
  • AdventHealth Orlando — Orlando
  • Tallahassee Research Institute — Tallahassee

Michigan

  • University of Michigan Medical Center — Ann Arbor
  • Henry Ford Providence Southfield Hospital — Southfield

New York

  • NYU Langone Health — New York
  • New York Presbyterian Hospital/Cornell University — New York

Arizona

  • HonorHealth — Scottsdale

Arkansas

  • Arkansas Heart Hospital — Little Rock

California

  • Stanford University Medical Center — Stanford

Colorado

  • South Denver Cardiology Associates PC — Littleton

Georgia

  • Piedmont Athens Regional Medical Center — Athens

Trial Details

FieldValue
Enrollment Target 188 participants
Start Date 2024-11-22
Est. Completion 2026-04-30
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06676072

The ClinicalTrials.gov registry entry for NCT06676072 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 1 intervention — of which PFA Ablation catheter is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06676072 reports 20 study locations spanning 16 distinct geographic areas — top geographies include Florida, Michigan, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06676072 about?

NCT06676072 is a clinical study titled "A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:". The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxys...

What is the current status of trial NCT06676072?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 188 participants. The study started on 2024-11-22. Estimated completion is 2026-04-30.

What conditions does trial NCT06676072 study?

This clinical trial studies the following conditions: Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06676072?

The interventions under investigation include: PFA Ablation catheter (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06676072?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06676072 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial